Abstract

Sinus node (SN) pacemaking is based on a coupling between surface membrane ion-channels and intracellular Ca2+-handling. The fundamental role of the inward Na+/Ca2+ exchanger (NCX) is firmly established. However, little is known about the reverse mode exchange. A simulation study attributed important role to reverse NCX activity, however experimental evidence is still missing. Whole-cell and perforated patch-clamp experiments were performed on rabbit SN cells supplemented with fluorescent Ca2+-tracking. We established 2 and 8 mM pipette NaCl groups to suppress and enable reverse NCX. NCX was assessed by specific block with 1 μM ORM-10962. Mechanistic simulations were performed by Maltsev–Lakatta minimal computational SN model. Active reverse NCX resulted in larger Ca2+-transient amplitude with larger SR Ca2+-content. Spontaneous action potential (AP) frequency increased with 8 mM NaCl. When reverse NCX was facilitated by 1 μM strophantin the Ca2+i and spontaneous rate increased. ORM-10962 applied prior to strophantin prevented Ca2+i and AP cycle change. Computational simulations indicated gradually increasing reverse NCX current, Ca2+i and heart rate with increasing Na+i. Our results provide further evidence for the role of reverse NCX in SN pacemaking. The reverse NCX activity may provide additional Ca2+-influx that could increase SR Ca2+-content, which consequently leads to enhanced pacemaking activity.

Details

Title
The reverse mode of the Na+/Ca2+ exchanger contributes to the pacemaker mechanism in rabbit sinus node cells
Author
Tóth, Noémi 1 ; Loewe, Axel 2 ; Szlovák, Jozefina 1 ; Kohajda, Zsófia 3 ; Bitay, Gergő 1 ; Levijoki, Jouko 4 ; Papp, Julius Gy. 5 ; Varró, András 5 ; Nagy, Norbert 5 

 University of Szeged, Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625) 
 Karlsruhe Institute of Technology (KIT), Institute of Biomedical Engineering, Karlsruhe, Germany (GRID:grid.7892.4) (ISNI:0000 0001 0075 5874) 
 ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary (GRID:grid.9008.1) 
 Orion Pharma, Espoo, Finland (GRID:grid.419951.1) (ISNI:0000 0004 0400 1289) 
 University of Szeged, Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625); ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary (GRID:grid.9008.1) 
Pages
21830
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2755191797
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.